0928 Novo Obesity

Product Development

Novo makes obesity pick as amylin/GLP-1 combo promises gastric bypass-like efficacy

With data in from five obesity programs, Novo pins hopes on amylin/GLP-1 combo

Novo is homing in on a semaglutide combination for obesity as it awaits CV outcomes data from the monotherapy that could convince more physicians to treat the condition.

Sep 25, 2020 | 10:44 PM GMT

Novo Nordisk is closing in on a one-two punch it believes could shift the treatment paradigm for obesity with the pick of an amylin/semaglutide combination as its next big therapy in the disease.

The combo is set to enter late-stage development in 2021, on the  heels of clinical data from a cardiovascular outcomes trial of Novo’s semaglutide monotherapy in obesity. The pharma hopes the evidence of the CVOT will persuade physicians of the

Read the full 1337 word article

How to gain access

Continue reading with a
two-week free trial.